Answers are grounded in this paper and cite their sources.
Background: D-dimer reflects thrombus formation and fibrinolysis and is associated with stroke severity and outcome, but whether it predicts post-stroke epilepsy (PSE) is unclear. We examined whether admission D-dimer predicts PSE and assessed its diagnostic and incremental predictive value in acute ischemic stroke (AIS). Methods: A total of 21,459 patients with AIS were analyzed. Admission D-dimer was divided into quartiles; the two lowest were merged as the reference. Multivariable logistic regression with three adjustment models, restricted cubic spline and subgroup analyses were performed. Discrimination (ROC/AUC), decision curve analysis, and the net reclassification index (NRI) and integrated discrimination improvement (IDI) assessed predictive value. Results: Within one year, 936 (4.4%) patients developed PSE. Each 1 mg/L increase in D-dimer was associated with higher PSE risk (fully adjusted OR 1.46, 95% CI 1.37-1.57); compared with the merged Q1+Q2 reference, fully adjusted ORs were 9.13 (Q3) and 15.23 (Q4) (P for trend < 0.001). The association was non-linear (P < 0.001), with a threshold at 0.867 mg/L, and was stronger in men, younger patients, and those without hypertension (P for interaction < 0.001). D-dimer discriminated PSE with an AUC of 0.822 (95% CI 0.810-0.835), higher than ALT, uric acid, creatinine and urea; adding it to a baseline model (age, gender, NIHSS, hypertension) raised the AUC from 0.866 to 0.920 (P < 0.001; NRI 0.8438, IDI 0.2031). Conclusions: Admission D-dimer was independently and non-linearly associated with PSE and improved discrimination and reclassification beyond conventional factors. It may aid early identification of AIS patients at high PSE risk.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: